Literature DB >> 7069434

Treatment of acute exacerbations of multiple sclerosis with intravenous methyl-prednisolone.

C Buckley, C Kennard, M Swash.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7069434      PMCID： PMC1083051          DOI： 10.1136/jnnp.45.2.179-a

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  9 in total

1.  FURTHER NOTES ON DISABILITY EVALUATION IN MULTIPLE SCLEROSIS, WITH SCALE MODIFICATIONS.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1965-07       Impact factor: 9.910

2.  Course of exacerbations of multiple sclerosis in hospitalized patients.

Authors:  J F KURTZKE
Journal:  AMA Arch Neurol Psychiatry       Date:  1956-08

3.  "Pulse" methylprednisolone therapy in the treatment of severe glomerulonephritis.

Authors:  B R Cole; J T Brocklebank; R A Kienstra; J M Kissane; A M Robson
Journal:  J Pediatr       Date:  1976-02       Impact factor: 4.406

Review 4.  Clinical pharmacology of systemic corticosteroids.

Authors:  J C Melby
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

5.  Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (A.C.T.H.).

Authors:  H MILLER; D J NEWELL; A RIDLEY
Journal:  Lancet       Date:  1961-11-18       Impact factor: 79.321

6.  Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis.

Authors:  H Link; G Tibbling
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

7.  Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.

Authors:  A S Rose; J W Kuzma; J F Kurtzke; N S Namerow; W A Sibley; W W Tourtellotte
Journal:  Neurology       Date:  1970-05       Impact factor: 9.910

Review 8.  Pathophysiology of demyelinating disease.

Authors:  A M Halliday; W I McDonald
Journal:  Br Med Bull       Date:  1977-01       Impact factor: 4.291

9.  Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis.

Authors:  E S Cathcart; B A Idelson; M A Scheinberg; W G Couser
Journal:  Lancet       Date:  1976-01-24       Impact factor: 79.321
  9 in total
  7 in total

1.  Intravenous methylprednisolone for multiple sclerosis in relapse.

Authors:  M P Barnes; D E Bateman; P G Cleland; D J Dick; T J Walls; P K Newman; M Saunders; P J Tilley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-02       Impact factor: 10.154

2.  Methylprednisolone in multiple sclerosis: a comparative dose study.

Authors:  L Bindoff; P R Lyons; P K Newman; M Saunders
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-08       Impact factor: 10.154

3.  Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects.

Authors:  P R Lyons; P K Newman; M Saunders
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-02       Impact factor: 10.154

4.  High dose intravenous methyl prednisolone in acute exacerbations of multiple sclerosis.

Authors:  J Y Goas; J L Marion; A Missoum
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-01       Impact factor: 10.154

Review 5.  Multiple sclerosis: diagnosis and the management of acute relapses.

Authors:  S M Leary; B Porter; A J Thompson
Journal:  Postgrad Med J       Date:  2005-05       Impact factor: 2.401

6.  Multiple sclerosis intra-blood-brain-barrier IgG synthesis: effect of pulse intravenous and intrathecal corticosteroids.

Authors:  R W Baumhefner; W W Tourtellotte; K Syndulko; A Staugaitis; P Shapshak
Journal:  Ital J Neurol Sci       Date:  1989-02

7.  A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.

Authors:  N M Milligan; R Newcombe; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-05       Impact factor: 10.154
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.